Marinus Pharmaceuticals competitors

• Pharmaceutical/Biotech executive with over 23 years’ experience in successful commercialization (sales, marketing, trade, managed markets, training and development, market research, sales operations, supply chain), general operations (IT, facilities), business development, leadership development, investor relations and strategic planning. • Proven track record of commercialization success in diverse business structures including large public pharma, start-up specialty private pharma and public biotech inclusive of building and scaling commercial operations to the needs of the organization. • Accomplishments include launching a blockbuster mass market brand/category, re-launching specialty and mass market brands to generate positive brand P&Ls, and corporate M&A leading to the exit of a specialty pharma company for $1.65B.

Dr. Roger Tung is the scientific founder, President, and CEO of Concert Pharmaceuticals, which he co-founded in 2006. Before Concert, Roger worked in venture-backed start-up and major pharmaceutical companies; including Vertex Pharmaceuticals, as a founding scientist and most recently Vice President of Drug Discovery; Merck; and E.R. Squibb & Sons. At Vertex, he co-invented the marketed HIV protease inhibitors Lexiva® and Agenerase®, and oversaw the discovery of Incivek® and Kalydeco®, approved respectively to treat HCV infection and cystic fibrosis caused by the G551D CFTR mutation. Roger has published widely and been granted 60 U.S. patents. He received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich. Roger is a scientific advisor to public and private biotech companies and serves on the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.

Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since August 2006. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.